Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: hpgrant who wrote (10482)	6/14/2018 9:43:53 AM
From: donpat	Respond to of 12873

It just looks probable to me. If, as and when it is a fact, I trust the companies will tell us. All we have to go on around here, or most boards, is our instincts and wits.

To: hpgrant who wrote (10482)	6/14/2018 9:44:51 AM
From: drkaz	Read Replies (2) \| Respond to of 12873

Agreed. There is no good reason to suspect that there is any outside entity is buying big (or small for that matter) into NNVC right now.

To: hpgrant who wrote (10482)	6/14/2018 11:58:53 AM
From: donpat	Read Replies (2) \| Respond to of 12873

Glaxo is very wealthy, very smart and very virus centric: 01 June 2018 GSK completes Consumer Healthcare buyout GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has completed the buyout of Novartis’ 36.5% stake in its Consumer Healthcare Joint Venture for $13 billion (£9.3 billion). The transaction, which was previously announced on 27 March 2018 and described in the circular published on 13 April 2018, was approved by shareholders on 3 May 2018. GSK - a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us. gsk.com They've just gotta have NNVC in their sights.*